

Dose Counting

Barbarah Martinez, MSN, APRN, FNP-BC May 7, 2025

TB Nurse Case Management • May 6 – 8, 2025 • San Antonio, Texas

Barbarah Martinez, MSN, APRN, FNP-BC

Has the following disclosures to make:

- No conflict of interests
- No relevant financial relationships with any commercial companies pertaining to this activity



DEPARTMENT OF PEDIATRICS





Dose Counting

Barbarah Martinez MSN, APRN, FNP-BC Instructor - Baylor College of Medicine May 7, 2025



Directly Observed Therapy

The main strategy to
Ensure TB patient adherence
Tolerability of prescribed
regimen


DOT can be in person or eDOT (VDOT)

ALL patients with TB disease should participate in DOT













Improving Tuberculosis Medication Adherence: The potential for Integrating Technology and the Health Belief Model

Literature Review using Pub Med and Google Scholar

Findings:

There is no standard definition of TB medication adherence

The World Health Organization (WHO) defines adherence as:

"The extent to which the patient follow medical instructions. Non-adherence to medication is a significant barrier to treatment of chronic diseases, including TB

Globally non-adherence to medication

- o 50 % in developed countries
- Higher in developing countries





Factors Influencing Medication Adherence

Factors:

- Patient Related
- Condition Related
- Therapy Related
- Health System Related
- Socioeconomic

Could nurse case managers or other healthcare providers influence these factors?





Patient Related Factors

Not Modifiable

- Male
- Lower age: <35
- Divorced
- Widowed

Modifiable

- Forgetfulness
- Lack of Knowledge/Understanding
- Psychological distress/Fear
- Stigma
- Social Acceptance of Traditional Medicine
- Lack of Family Support





Disease Factors

Condition

- Pill Burden
- Depression
- Co-morbidities



Therapy

- Side effects/Adverse effects
- Feeling better
 - Non-adherence increases during the continuation phase





Systemic Factors

Health Care System

- Poor provider/patient relationship
- Inflexible schedule for DOT
- Health care workforce attitude
- Training of health care workers
- Overburdened Health System

Socioeconomic

- Lack of access to care
- Situational increased risk of exposure
- Lack of financial support
- Poor or No transportation





Human Behavior Model

- Appropriate Perception of Self Vulnerability
- Perceived Seriousness of Nonadherence
- Self-Confidence to Adhere
- Self-Belief in the Benefits of Medication
- Self-Confidence to Adhere


Can nurse case managers/healthcare workers help patients with the behaviors for successful completion of therapy?







Adherence and Completion of Therapy



Adherence and completion of therapy intersect





Let's Review- For a Standard RIPE Regimen

To figure out the number of doses a patient needs to complete therapy:

Number of days of the week the patient is expected to take **observed** doses X the total number of weeks the patient is prescribed treatment.

In person DOT by Health Department

Expected observed doses = 5 days a week

VDOT or In person DOT by a facility (hospital/correctional facilities)

Expected observed doses = 7 days a week







Some More Review

How many weeks is a person expected to complete if they are to receive 6 months of therapy?

26 weeks

How many weeks is a person expected to complete if they are to receive 9 months of therapy?


39 weeks





Let's Compare

Mary is expected to complete 6 months of therapy on VDOT



Mary is expected to complete 6 months of therapy via in-person DOT

- Duration in weeks for 6 months:
 - 26 weeks
- Number of days per week she is anticipated to be observed:
 - 5 days

Calculating gives $26 \times 5 = 130$.





WAIT... Why are we making those on DOT Finish more Doses?



•Patients receiving in-person Directly Observed Therapy (DOT) are expected to take their own medications on weekends. While these doses cannot be counted in completion totals since they are not observed, they do aid in the overall cure.

Therefore, it is essential to

- •Regularly remind patients that completing all doses is vital for curing the disease. Do not tell them they only need to complete 130 doses or that their weekend doses "do not count". All doses ingested whether observed or selfadministered **count towards CURE**.
- •The expectation is that **all** patients complete a total of 182 doses, including the self-administered weekend doses.





Let's Break It Down Further - Initial Phase of Therapy

TB treatment is divided into two phases: the initial phase and the continuation phase

Initial Phase:

- The initial phase of treatment consistently lasts for 8 weeks.
- The patient must complete the required number of doses within a 12-week timeframe.
- Therapy interruptions must not exceed 14 consecutive days or patients gets a "do over".
- Any doses taken prior to the interruption cannot be counted towards completion.
- The patient **cannot** progress to the continuation phase until susceptibility results are received.
 - INH mono-resistance in US 9-11 %
- Rifampin mono-resistance in US approximately 1%
 - If Rifampin resistance GET A CONSULT. Patient considered to have at least MDR TB.
- During initial phase, the patient receives INH, Rifampin, EMB, PZA, and B6.
- If PZA not included initially the patient MUST complete 9 months of therapy.





And -Continuation Phase of Therapy

- The length of the continuation phase varies depending on the total length of therapy
 - For 6 months or 26 weeks 18 weeks
 - For 9 months or 39 weeks 31 weeks
- **DO NOT** advance to continuation phase if you do not have susceptibilities
 - PZA may be dropped after two months if:
 - Negative Smear/Negative Culture
 - Clinical case of TB.
 - INH mono-resistance in US 9-11% of cases
 - Rifampin mono-resistance in US 1% of cases
 - If Rifampin resistance patient is to be treated as if they have MDR (OBTAIN A CONSULT)
- Usually consists of INH, Rifampin and Vitamin B6
- There cannot be an interruption longer than 3 months or patient must start all over again
 - Sputum collection, medical evaluation and CXR





Case Study

- Maria is a 36-year-old female born in Mexico who was reported by the local correctional facility after she was evaluated at the local hospital for signs and symptoms of TB.
- Maria reported to the correctional facility staff that she coughed up blood the night before and that she was waking up drenched in sweat and that she had a cough that has lasted for several weeks. She also reported that she has lost her appetite and really does not feel like eating.
- Maria denies any contributing PMHX
- She denies any IV drug use or smoking
- She has been unhoused
- Currently lives with a friend and his children- no one at the house was sick.






Maria's Hospital Stay and Bacteriology Results

- Maria was admitted for TB workup after the cavitary findings on the CXR.
- Sputum was collected on 2/14, 2/15 and 2/16 and a NAAT was sent on the sputum collected on 2/14: Findings below
 - >10 AFB seen on smear
 - NAAT
 - MTB detected
 - Rifampin resistance not detected (Copy de-identified bacteriology and NAAT here)
- Maria's weight on admission was 62 kg
- HIV was non-reactive
- A1C = 8.9













Status: Final result Visible to patient: Yes (not seen)

0 Result Notes

Component Ref Range & Units	
WBC	5.48
4.19 - 9.43 x 10*3/uL	
RBC	4.96 ^
3.93 - 4.90 x 10*6/uL	
HGB	11.1
10.8 - 13.3 g/dL	
HCT	36.6
33.4 - 40.4 %	
MCV	73.8 🗸
76.9 - 90.6 fL	12.12.4
MCH	22.4 🗸
24.8 - 30.2 pg	
MCHC	30.3 🗸
31.5 - 34.2 g/dL	
RDWCV	15.0 ^
12.3 - 14.6 %	
RDWSD	39.3
37.1 - 44.2 fL	
Platelet	461 ^
194 - 345 x 10*3/uL	
MPV	8.7 🗸
9.6 - 11.7 fL	





▲ Liver Panel

Status: Final result Visible to patient: Yes (not seen)

0 Result Notes

Component	
Ref Range & Units	
Alkaline Phosphatase	90
45 - 116 U/L	
ALT	14
10 - 35 U/L	
AST	29
5 - 30 U/L	
Bilirubin Conjugated	0.0
0.0 - 0.3 MG/DL	
Bilirubin Unconjugated	0.2
0.0 - 1.0 MG/DL	
GGT	11
11 - 28 U/L	
Albumin	3.7
3.5 - 5.2 G/DL	



Maria's TB Regimen While in Hospital

- Maria was started on RIPE on February 15, 2025, with the following: Maria's weight is **62kg**
- INH 300 mg po daily
- Rifampin 600 mg po daily
- EMB 800 mg po daily
- PZA 1000 mg po daily
- Vitamin B6 50 mg po daily

Are these doses correct for Maria?





Dosing for Adults

TABLE 2. Doses of First-Line Anti-Tuberculosis Drugs for ADULTS

Daily Dosing					
Weight (kg) Based on estimated lean body weight ¥	Isoniazid[*] (INH) Dose, mg (mg/kg)	Rifampin^{**} (RIF) Dose, mg (mg/kg)	Pyrazinamide (PZA) Dose, mg (mg/kg)	Ethambutol (EMB) Dose, mg (mg/kg)	
40-55 kg	300 [†] mg (5mg/kg)	600 mg (10-20mg/kg [‡])	1,000 mg (18.2-25.0)	800 mg (14.5-20.0)	
56-75 kg			1,500 mg (20.0-26.8)	1,200 mg (16.0-21.4)	
76-90 kg			2,000 [†] mg (22.2–26.3)	1,600 [†] mg (17.8-21.1)	
Thrice (3x) Weekly Dosing – <i>Consultation Required</i>					
Weight (kg) Based on estimated lean body weight ¥	Isoniazid* (INH) Dose, mg (mg/kg)	Rifampin^{**} (RIF) Dose, mg (mg/kg)	Pyrazinamide (PZA) Dose, mg (mg/kg)	Ethambutol (EMB) Dose, mg (mg/kg)	
40-55 kg	900 [†] mg (15mg/kg)		1,500 mg (27.3-37.5)	1,200 mg (21.8-30.0)	
56-75 kg		600 mg (10-20mg/kg)	2,500 mg (33.3-44.6)	2,000 mg (26.7-35.7)	
76-90 kg			3,000 [†] mg (33.3-39.5)	2,400 [†] mg (26.7–31.6)	
Forms available	Scored tablets: 100 mg, 300 mg and Syrup (50mg/5ml)	Capsule: 150 mg, 300 mg Contact DSHS for compounding	Scored tablets: 500 mg	Tablets : 100 mg, 400 mg	





Let's Get Our Calendar's Out.

Maria was in the hospital from 2/15/25 to 2/18/25. She received dosing below the recommended amounts on 2/15/25

Maria received all doses of TB meds as per below on 2/16/25 and 2/17/25

INH 300 mg po q am

Rifampin 300 mg po am and pm

EMB 600 mg q and 600 mg q pm

PZA 1000 mg po am and 500 mg q pm

Would you count these doses? Why or Why not?

The preferred frequency is once daily for both the intensive and continuation phases

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis






Let's Continue

- Maria stayed in the hospital from 2/15/25 to 2/22/25 but appropriate dosing was not started until 2/18/25
- So how many doses did Maria complete in the hospital?
- 4 doses
- Maria returned to the correctional facility and continued to receive her RIPE appropriately from 2/23/25 to 4/3/25
- The current plan is to treat Maria for 9 months she has a cavitary CXR. She is newly diagnosed with T2DM with an A1C of 8.9












So how much treatment has Maria received so far?

- How many doses?
 - 46 doses
- How many weeks?
 - 6.5 weeks
- Has she been adherent with her regimen?
 - Yes





LET THE GAME BEGIN, CAN WE BRING MARIA ACROSS HOME PLATE?







Maria Is Released

- Maria is released on April 3rd but you are **not** notified
- The address you have for Maria is **not** correct
- The phone is working but when you call, the man who answers the phone tells you Maria is not available.
- You and your team continue to search Maria and find her on April 28th when she finally answers the phone, and you can get an accurate address.













Figure 5.2
Algorithm for Management of Intensive-Phase Treatment Interruptions



CORE CURRICULUM ON TUBERCULOSIS: WHAT THE CLINICIAN SHOULD KNOW SEVENTH EDITION 2021





Break in Treatment

- How long was the break in treatment during the initial phase of therapy?
- 25
- More or less than 14 consecutive days?
- More
- Does any of the treatment before you were unable to find her count towards completion of therapy?
- No





Home Visit

• You make a home visit to Maria, and she tells you that she had not wanted to take her medicines because she went to her "curandera" who gave her some herbal medication that she said would cure her TB.

What would you do???



• You also notice that there are three children in the home ages 3 months, 2 years and 7 years of age.... (Keep these ages in the back of your mind for now)





Home Visit


- You have a long discussion with Maria, and you ask to see what the herbal medicines are. It is a mixture of basil, chamomile and rosemary. You encourage to keep taking the tea the curandera has provided her but also are able to educate her on the need for her to take her TB meds.
- The patient verbalizes understanding and agrees to take the DOT

What question could you ask to ensure patients tell you about all the pills/supplements they take? Why is it important to know?









2025 Calendar



January O1						
8un	Mon	Tue	Wed	Thu	FrI	8at
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	
Ap	ril				O	4

April					O	4
Sun	Mon	Tue	Wed	Thu	FrI	8at
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

]	February				O	2	
	8un	Mon	Tue	Wed	Thu	FrI	8at
							1
	2	3	4	5	6	7	8
	9	10	11	12	13	14	15
	16	17	18	19	20	21	22
	23	24	25	26	27	28	29

]	May					O	5
_	3un	Mon	Tue	Wed	Thu	Frl	8at
						1	2
	3	4	5	6	7	8	9
	10	11	12	13	14	15	16
	17	18	19	20	21	22	23
	24	25	26	27	28	29	30
	31						

Ma	ırcl	n		O	3	
8un	Mon	Tue	Wed	Thu	FrI	8at
1	2	3	4	5	6	Z
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

Jur	ıe		O	O			
8un	Mon	Tue	Wed	Thu	FrI	8at	
	1	2	3	4	5	6	I
7	8	9	10	11	12	13	
14	15	16	17	18	19	20	
21	22	23	24	25	26	27	
28	29	30]





Reviewing Adherence

Based on the calendar, what is Maria's start date of treatment?

4/28/25

How many weeks of therapy has she completed?

35 doses 35/7 = 5 weeks

As you start looking ahead since she is almost done with the initial phase of therapy what are some things that you should be reviewing before you advance?


- Susceptibilities
- Repeat CXR?
- Symptom Improvement?
- Adverse Drug effects?





There is Always a Curve Ball.... Are you ready for it?

- Maria has completed 5 weeks of DOT with RIPE without any complaints.
- On June 4th Maria contacts you complaining of the following:
- Nausea
- Vomiting
- Rash all over body
- Fever of 101
- Headache
- N/V



NOW WHAT???





Medical Evaluation – What Do You Do?

You make an emergent appointment for Maria Your clinic provider asks to hold meds, draws a CBC and Liver enzymes with the following results:

WBC 11.28

RBC 4.70

Hgb 13.0

HCT 38.2

Platelets 150

ALT 191

AST 93





Consult with Heartland

Consult from Heartland:

- "Let the liver cool down" Levels back down to less than 2x ULN Start a drug challenge as follows:
- Rifampin 600 mg and EMB 1200 mg daily x 7 days if no problems,
- Add INH 300 mg daily x 7 days if no problems
- Add PZA 1500 x 7 days, if no problem continue regimen to complete the initial phase of therapy.


What would you communicate with Maria? How would you encourage her to continue treatment?







Calendar



•	`	1	ı
•	,	J	L



	8un	Mon	Tue	Wed	Thu	FrI	8at
							1
	2	3	4	5	6	7	8
	9	10	11	12	13	14	15
I	16	17	18	19	20	21	22
	23	24	25	26	27	28	29

						$\overline{}$
8un	Mon	Tue	Wed	Thu	FrI	8at
1	2	3	4	5	6	Z
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				



т.	Æσ	~ -
- 11	/1 /	ч١
		~.)

March

_	_	•	-
•	•	•	•
٧.	,	٠.	,

			1	2	3
5	6	7	8	9	10
12	13	14	15	16	17
19	20	21	22	23	24
26	27	28	29	30	

Sun Mon Tue Wed Thu Fri

					_	_
8un	Mon	Tue	Wed	Thu	Frl	8at
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						

Sun	Mon	Tue	Wed	Thu	Fri	8at
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				



PEDIATRICS



Do any of the Doses Count Prior to the Drug Challenge Count Towards Completion?

- Her treatment start date is 4/28/25
- How long is the latest break in treatment?
- 11 days so far
- Do the doses during the challenge count when you are introducing one drug at a time?
 - Only regimens that are considered therapeutic are counted towards completion





Here Comes the FASTBALL

The meds are on hold until the LFT's are below 2 x ULN and the platelets have recovered to 195

You start the drug challenge with Rifampin and EMB on 6/15/25.

On the fourth day of the challenge, Maria calls with the following complaints:

- Headache
- Rash
- Fever
- Malaise









Because You Don't want Dr. Armitige or Dr. Seaworth To Miss you....

- You get a second consult.
- This time the recommendation is to re-start the challenge but to substitute Rifabutin for Rifampin











Jar	ıua		O	1		
Sun	Mon	lue	Wed	Ilhu	hm	Set
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

Ap	ril	O	4			
Sun	Mon	lue	Wed	lhu	hn	Set
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		
r						


July O								
Sun	Mon	lue	Wed	lhu	hn	Set		
			1	2	3	4		
5	6	7	8	9	10	11		
12	13	14	15	16	17	18		
19	20	21	22	23	24	25		
26	27	28	29	ÞО	31			

February					O	2
Sun	Mon	lue	Wed	lhu	hn	Set
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
					_	=

Ma	ıy	O	5			
Sun	Mon	lue	Wed	lhu	hn	Set
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						
						$\overline{}$

Au	gus	O	8			
Sun	Mon	lue	Wed	Ilhu	hm	Set
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31					

Ma	rch		O	3		
Sun	Mon	lue	Wed	Ilhu	hn	Set
1	2	3	4	5	6	Z
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				
						_



Sej	ote:		O	9		
Sun	Mon	lue	hn	Sat		
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30			

Rifabutin and EMB from 6/29 to 7/5

INH, Rifabutin and EMB from 7/6 to 7/12

INH, Rifabutin, EMB and PZA from 7/12 to 7/19

Do you count the doses of a drug challenge?

If so, when would you start counting doses?

Does the patient need to start treatment over?

How many doses of therapy has Maria completed?





I have been on treatment since February. I don't want MORE...

- Maria does not want to continue therapy because she has been on treatment for 8 months.
- How would you encourage Maria to continue her therapy?
- You have received the susceptibilities, and the specimen is found to be PAN sensitive
- Maria took almost 3 months to convert her culture.
- Maria's CXR in April showed minimal improvement
- Maria's CXR in June showed improvement as compared to the April CXR but the cavitary lesion can still be seen
- Today's CXR shows complete resolution of the cavitary lesion.
- Decision is made to treat for 9 months and to repeat the CXR before Maria completes therapy





Can we advance to the Continuation Phase, yet???

Things we know:

The organism is PAN-susceptible


Maria's X-ray and symptoms are improving.

We have found a regimen that Maria can tolerate, and we are supporting her cultural beliefs













Let's do some math

How many doses has Maria taken since starting her treatment? 56 doses

In how many weeks did she finish the initial phase of therapy? 56/7=8 (Doses/# of expected observed doses per week = weeks)

How many weeks and how many doses of therapy would Maria have finished if she had only received 48 doses?

42/7= 6 Maria has finished 6 weeks of therapy

8-6= 2 Maria has two weeks left to finish her initial phase of therapy

2x7 = 14 Maria has 14 doses left to complete the initial phase of therapy

If Maria misses 5 doses, will she complete the initial phase of therapy in the 12 weeks that are required per our calendar?














2025 Calendar



Jan	January O							
M inor	Marin	T	West	The	(Mail	Model		
			+	521	29	-4-		
25	10	3"	101	- 10	1900	**		
112	10	754	1.5	166	477	4.0		
119	20	211	2.2	2.3	25.41	285		

200

Ap:	ril		O	4		
(Minute)	Marin	Time	*Williams	Tiles	(Mari	Shell
			-	-	536	- 4
85	103	Ŧ	101	0	70	11.1
712	1.3	754	1.5	765	477	+ 60
-100	:28:03	28.4	:28:28	:2:3	:2:-4	:285
265	:27	28	20	30		

Jul	37				O	7
	Marin	T	West	Time	Mail	Mark
			-1	52	59	- 4
55	100	37	100	9	70	44
112	10	79.46	115	196	47	100
110	2.0	23.11	22	2.3	24	285
266	27	20	29	:0:0	32.7	

O-cr	bolb	er			1	\mathbf{O}
(Minute)	Marin	T	West	Title	(Mail)	Model
				4	521	3-
4.	25	15	37	100	100	10
77	12	4.3	75-66	1.5	1965	17
40	19	200	27	-2:2	2.0	2246
25	26	27	:28	210	30	5311

Fel	bru		O	2		
Show	Marin	T	Williams	The	Photo:	Mont
						+
20:	29	46	55	15	3"	(0)
- 10	10	71.71	4.2	7:3	7.4	71.55
7.03	17	-	-	200	27	22
225	25.00	25	28	27	20	200
IMDa	rae				O	

					700	-
M inance	Missen	Terr	Without	Tiles	Part .	Morel
					- +	22
26	4.	5	65	27	- 0	- 0
10	11	4.2	7.0	75-4	1.5	1946
47	100	1910	20	2.1	2.2	2.0
22-6	25	24	27	2.0	2.0	30
201						

494000	August 🔾								
· ·	Marin	7-	West	The	(Mari	- Married			
						4			
201	59		55	15	T	- 10			
- 0	100	77	4.2	71.0	194	71.5			
10	17	7.0	718	:2:0	23.7	:2:2			
23	2.4	2.5	2.6	27	2.0	2.0			
290	:01 11								

No	ver	1	1			
(Moreon	Miles	7-	Witnesd	Title	(Mail	- March
4	22	59	4.	55	65	37
-	- 0	700	2.2	4.2	4.0	75-44
105	165	47	4.0	71.00	20	2.4
222	:2:3	:2.4	2.5	:2:5	27	:2:0
299	:3:0					

	mah		74	"		
	Marin	There	Witnesd	Time	19541	- March
=	2	56	-	8	-	-
•	•	-				
715	-	-	-	-	20	27
100	20	25.00	25	200	27	200
120	50	95				

June OO									
M	Marin	There	Williams	Wheel	1994	Mont			
	4	521	29	4.	55	103			
Ŧ	a	100	70	7171	7.2	113			
75-4	1.5	16	47	10	7-3	:20			
22.11	:2:2	:2:0	:2:-4	:2.5	:2:5	:27.7			
2.6	29	30							


Sep	otie:	O	9			
Mary .	160mm	T	*Witness	Tile	(Mail	Marri
		+	52	55	40.	25
15	37	100	150	100	77	112
19:00	71-01	4.5	765	47	200	19
:20-01	2.1	22	2.5	24	2.5	26
27	20	20	30			

December					12	
	Marin	Time	What	Time	(864)	Barri
		4	521	29	4	55
15	37	101	100	90	2.2	92
4.0	75-64	1.5	1965	47	200	10
20	27	22	23	22-4	2.5	:2:6
27	2.0	:2:0	:0:0	:0.1		





Figure 5.3
Algorithm for
Management of
Continuation
Phase
Treatment
Interruptions



Abbreviation: AFB, acid-fast bacilli.





Am I done YET???

- The patient completed
- 56 doses /7 days a week of RIPE = 8 weeks
- 78 doses/7 days a week of IR= 11 weeks

Total weeks completed =18

How many weeks does the patient have left?

39 weeks (9 months) -18 weeks of completed doses = 21 more weeks of therapy

How many more doses does Maria have left?

21x7 = 147 doses






Remember the Kids???

- Which children should be your priority for evaluation? Why?
- Do any of the children require window prophylaxis?
- Why would a pediatric TB provider need to know and keep bugging you about the adult susceptibilities
- What information would be important for you to share with the pediatric provider?

Your homework will be to familiarize yourself with the dosing of TB meds for kids!











Remember the factor?

There is a lot that you as nurse case manager can do to help the patients modify their behavior.

The Four Pillars of Nursing:

- Clinical Practice
- Education
- Research
- Leadership





You are your patient's voice!


Patient Advocacy is a *core* and *essential* function of nursing.

It is fundamental to ethical practice and patientcentered care




























Thank you for all you do every day for those who may not have a voice!







References

American Nurses Association. (2023). Code of ethics for nurses. American Nurses Publishing.

Centers for Disease Control and Prevention (2024). TB 101 for Health Care Workers. Retrieved from: https://www.cdc.gov/tb/webcourses/TB101/index.html

Centers for Disease Control and Prevention (2024). Core Curriculum on Tuberculosis: What the clinician should know. Retrieved from:

https://www.cdc.gov/tb/hcp/education/core-curriculum-on-tuberculosis.html

Texas Department of State Health Services (2024, August 30). Texas Department of State Health Services Standing Delegation Orders for Tuberculosis Clinical Services Provided by Authorized Licensed Nurses,. *Retrieved from https://www.Dshs.Texas.gov/Sites/Default/Files/LIDS-TB/Policies/TB-SDO-ClinicalServicesforNurses-25.pdf*.

Sazali, M. F., Rahim, S. S. S. A., Mohammad, A. H., Kadir, F., Payus, A. O., Avoi, R., Jeffree, M. S., Omar, A., Ibrahim, M. Y., Atil, A., Tuah, N. M., Dapari, R., Lansing, M. G., Rahim, A. A. A., & Azhar, Z. I. (2023). Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model. *Tuberculosis and respiratory diseases*, 86(2), 82–93. https://doi.org/10.4046/trd.2022.0148S





Questions and Contact Information



Contact Information: <u>Barbarah.Martinez@bcm.edu</u> or <u>bxmart23@texaschildrens.org</u>

Work cell: 346-257-1275

Office Number: 832-824-4324



